{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:17:56Z","timestamp":1791645476263,"version":"4.3.4"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"\n Importance<\/jats:title>\n The US lacks a systematic approach for aligning drug prices with clinical benefit, and traditional cost-effectiveness analysis (CEA) faces political obstacles. The efficiency frontier (EF) method offers policymakers an alternative approach.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess how the EF approach could align prices and clinical benefits of biologic medications for plaque psoriasis and estimate price reductions in the US vs 4 peer countries: Australia, Canada, France, and Germany.<\/jats:p>\n <\/jats:sec>\n \n Design and Setting<\/jats:title>\n This health economic evaluation used the EF approach to compare the prices and clinical benefits of 11 biologics and 2 biosimilars for plaque psoriasis in the US, Australia, Canada, France, and Germany. Data were collected from February to March 2023 and analyzed from March to June 2023.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome Measures<\/jats:title>\n EFs were constructed based on each biologic\u2019s efficacy, measured using the Psoriasis Area and Severity Index (PASI) 90 response rate, and annual treatment cost as of January 2023; US costs were net of estimated manufacturer rebates. Prices based on the EF were compared with traditional CEA-based prices calculated by the Institute for Clinical and Economic Review at a threshold of $150\u202f000 per quality-adjusted life-year gained.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 13 biologics, PASI 90 response rates ranged from 17.9% (etanercept) to 71.6% (risankizumab); US net annual treatment costs ranged from $1664 (infliximab-dyyb) to $79\u202f277 (risankizumab). The median (IQR) net annual treatment cost was higher in the US ($34\u202f965 [$20\u202f493-$48\u202f942]) than prerebate costs in Australia ($9179 [$6691-$12\u202f688]), Canada ($15\u202f556 [$13\u202f017-$16\u202f112]), France ($9478 [$6637-$11\u202f678]), and Germany ($13\u202f829 [$13\u202f231-$15\u202f837]). The US EF included infliximab-dyyb (PASI 90: 57.4%; annual cost: $1664), ixekizumab (PASI 90: 70.8%; annual cost: $33\u202f004), and risankizumab (PASI 90: 71.6%; annual cost: $79\u202f277). US prices for psoriasis biologics would need to be reduced by a median (IQR) of 71% (31%-95%) to align with those estimated using the EF; the same approach would yield smaller price reductions in Canada (41% [6%-57%]), Australia (36% [0%-65%]), France (19% [0%-67%]), and Germany (11% [8%-26%]). Except for risankizumab, the EF-based prices were lower than the prices based on traditional CEA.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This economic evaluation showed that for plaque psoriasis biologics, using an EF approach to negotiate prices could lead to substantial price reductions and better align prices with clinical benefits. US policymakers might consider using EFs to achieve prices commensurate with comparative clinical benefits, particularly for drug classes with multiple therapeutic alternatives for which differences can be adequately summarized by a single outcome measurement.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.6236","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T11:01:39Z","timestamp":1708513299000},"page":"409","source":"Crossref","is-referenced-by-count":22,"title":["Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis"],"prefix":"10.1001","volume":"160","author":[{"given":"Alexander C.","family":"Egilman","sequence":"first","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Avorn","sequence":"additional","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J. N.","family":"Raymakers","sequence":"additional","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin N.","family":"Rome","sequence":"additional","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"doi230076r1","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1001\/jama.2022.15268","article-title":"New reforms to prescription drug pricing in the US: opportunities and challenges.","volume":"328","author":"Hwang","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"doi230076r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.5218","article-title":"Simulated Medicare drug price negotiation under the Inflation Reduction Act of 2022.","volume":"4","author":"Rome","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"4","key":"doi230076r3","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/milq.v99.4","article-title":"Pursuing value-based prices for drugs: a comprehensive comparison of state prescription drug-pricing boards.","volume":"99","author":"Bendicksen","year":"2021","journal-title":"Milbank Q"},{"issue":"3","key":"doi230076r4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1177\/1073110520958885","article-title":"An international review of health technology assessment approaches to prescription drugs and their ethical principles.","volume":"48","author":"Rand","year":"2020","journal-title":"J Law Med Ethics"},{"issue":"1","key":"doi230076r6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10198-017-0871-0","article-title":"Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.","volume":"19","author":"Angelis","year":"2018","journal-title":"Eur J Health Econ"},{"key":"doi230076r7","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1111\/j.1524-4733.2009.00515.x","article-title":"QALYs: the basics.","volume":"12","author":"Weinstein","year":"2009","journal-title":"Value Health"},{"issue":"9","key":"doi230076r9","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1377\/hlthaff.2021.00343","article-title":"Controversy over using quality-adjusted life-years in cost-effectiveness analyses: a systematic literature review.","volume":"40","author":"Rand","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"24","key":"doi230076r11","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1001\/jama.2023.8695","article-title":"Congress\u2019 misguided plan to ban QALYs.","volume":"329","author":"Rand","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"doi230076r13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/hesr.v58.2","article-title":"Alternatives to the quality-adjusted life year: how well do they address common criticisms?","volume":"58","author":"Rand","year":"2023","journal-title":"Health Serv Res"},{"issue":"5","key":"doi230076r14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/14737167.2018.1497976","article-title":"The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing: combining the best of both worlds?","volume":"18","author":"Sandmann","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"10","key":"doi230076r15","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/hec.v19:10","article-title":"The efficiency frontier approach to economic evaluation of health-care interventions.","volume":"19","author":"Caro","year":"2010","journal-title":"Health Econ"},{"issue":"8","key":"doi230076r16","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States.","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"6","key":"doi230076r17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","article-title":"Economic burden of psoriasis in the United States: a systematic review.","volume":"151","author":"Brezinski","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"21","key":"doi230076r18","first-page":"S403","article-title":"Contemporary management of moderate to severe plaque psoriasis.","volume":"23","author":"Wu","year":"2017","journal-title":"Am J Manag Care"},{"issue":"19","key":"doi230076r19","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review.","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"10","key":"doi230076r20","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1001\/jamadermatol.2020.2685","article-title":"Trends in list and net prices of self-administered systemic psoriasis therapies manufactured by US-based pharmaceutical companies.","volume":"156","author":"Ferris","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"10","key":"doi230076r21","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jamadermatol.2021.3616","article-title":"Out-of-pocket costs of specialty medications for psoriasis and psoriatic arthritis treatment in the Medicare population.","volume":"157","author":"Pourali","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi230076r22","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jaad.2022.06.1164","article-title":"A retrospective claims analysis confirms the cost of most biologic agents for psoriasis is increasing more rapidly than medical inflation.","volume":"88","author":"Patel","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi230076r23","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1080\/09546634.2020.1864265","article-title":"Psoriasis drugs in the Medicare population: dermatologists\u2019 spending and prescription patterns.","volume":"33","author":"Yang","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"doi230076r24","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi230076r26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis.","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi230076r28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jdermsci.2020.06.003","article-title":"Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.","volume":"99","author":"Tada","year":"2020","journal-title":"J Dermatol Sci"},{"key":"doi230076r29","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.618163","article-title":"A systematic review with network meta-analysis of the available biologic therapies for psoriatic disease domains.","volume":"7","author":"Torres","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"doi230076r31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jdv.2015.29.issue-4","article-title":"PASI90 response: the new standard in therapeutic efficacy for psoriasis.","volume":"29","author":"Puig","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi230076r32","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","article-title":"Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data.","volume":"85","author":"Shear","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"doi230076r33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub2","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"doi230076r35","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1377\/hlthaff.2018.05207","article-title":"Using external reference pricing in Medicare Part D to reduce drug price differentials with other countries.","volume":"38","author":"Kang","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"doi230076r36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.12927\/hcpol","article-title":"Use of product listing agreements by Canadian provincial drug benefit plans.","volume":"8","author":"Morgan","year":"2013","journal-title":"Healthc Policy"},{"issue":"1","key":"doi230076r38","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/1471-2458-12-439","article-title":"The weight of nations: an estimation of adult human biomass.","volume":"12","author":"Walpole","year":"2012","journal-title":"BMC Public Health"},{"issue":"6","key":"doi230076r40","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.0626","article-title":"Estimating rebates and other discounts received by Medicare Part D.","volume":"2","author":"Feldman","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"9","key":"doi230076r43","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold.","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"doi230076r44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdin.2021.06.004","article-title":"Biologics for severe, chronic plaque psoriasis: an Australian cost-utility analysis.","volume":"5","author":"Sun","year":"2021","journal-title":"JAAD Int"},{"issue":"15","key":"doi230076r45","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1001\/jama.2023.4034","article-title":"Added therapeutic benefit of top-selling brand-name drugs in Medicare.","volume":"329","author":"Egilman","year":"2023","journal-title":"JAMA"},{"issue":"10","key":"doi230076r46","doi-asserted-by":"publisher","first-page":"e989","DOI":"10.1212\/WNL.0000000000207544","article-title":"Variation in endpoints in FDA medication approvals: a review of acute and preventive migraine medications.","volume":"101","author":"Sharpless","year":"2023","journal-title":"Neurology"},{"key":"doi230076r5","unstructured":"Mulcahy? AW, Whaley? CM, Gizaw? M, Schwam? D, Edenfield? N, Becerra-Ornelas? AU. International prescription drug price comparisons: current empirical estimates and comparisons with previous studies. RAND Corporation. 2021. Accessed September 18, 2023. https:\/\/www.rand.org\/pubs\/research_reports\/RR2956.html"},{"key":"doi230076r8","unstructured":"Advocates for people with disabilities, chronic conditions and older adults request policymakers reject health policies that discriminate. American Association of People with Disabilities. April 14, 2021. Accessed September 18, 2023. https:\/\/www.aapd.com\/advocates-for-people-with-disabilities-chronic-conditions-and-older-adults-request-policymakers-reject-health-policies-that-discriminate\/"},{"key":"doi230076r10","unstructured":"Seshamani? M. Medicare Drug Price Negotiation Program: revised guidance, implementation of Sections 1191\u20131198 of the Social Security Act for initial price applicability year 2026. June 30, 2023. Accessed September 18, 2023. https:\/\/www.cms.gov\/files\/document\/revised-medicare-drug-price-negotiation-program-guidance-june-2023.pdf"},{"key":"doi230076r12","unstructured":"Alternatives to QALY-based cost-effectiveness analysis for determining the value of prescription drugs and other health interventions. National Council on Disability. November 28, 2022. Accessed September 18, 2023. https:\/\/ncd.gov\/sites\/default\/files\/NCD_Alternatives_to_the_QALY_508.pdf"},{"key":"doi230076r25","unstructured":"Drugs@FDA: FDA-approved drugs. US Food and Drug Administration. Accessed September 18, 2023. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"key":"doi230076r27","unstructured":"Banken? R, Agboola? F, Ellis? A, . Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. Institute for Clinical and Economic Review. August 3, 2018. Accessed September 18, 2023. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Psoriasis_Update_Final_Evidence_Report_10042018.pdf"},{"key":"doi230076r30","unstructured":"Noble? JH. Evolution of psoriasis endpoint use. IQVIA. July 31, 2020. Accessed September 18, 2023. https:\/\/www.iqvia.com\/blogs\/2020\/07\/evolution-of-psoriasis-endpoint-use"},{"key":"doi230076r34","unstructured":"NAVLIN price & access data. Eversana. Accessed September 18, 2023. https:\/\/www.eversana.com\/ko\/products\/pricentric-one\/"},{"key":"doi230076r37","unstructured":"Population of Canada by province\/territory 2021\/2022. Canada Population. Accessed September 18, 2023. https:\/\/canadapopulation.org\/population-of-canada-by-province-territory\/"},{"key":"doi230076r39","unstructured":"Exchange rates API. Oanda. Accessed September 18, 2023. https:\/\/www.oanda.com\/foreign-exchange-data-services\/en\/exchange-rates-api\/"},{"key":"doi230076r41","unstructured":"Ippolito? B, Levy? J. Best practices using SSR Health net drug pricing data. HealthAffairs. March 10, 2022. Accessed September 18, 2023. https:\/\/www.healthaffairs.org\/do\/10.1377\/forefront.20220308.712815\/"},{"key":"doi230076r42","unstructured":"2020-2023 Value Assessment Framework. Institute for Clinical and Economic Review. January 31, 2020. Updated October 23, 2020. Accessed September 18, 2023. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_2020_2023_VAF_102220.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2815167\/jamadermatology_egilman_2024_oi_230076_1713299746.11153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T11:13:04Z","timestamp":1713352384000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2815167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.6236","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}